Introduction
p73 is a member of the p53 protein family of transcription factors. p73 and p53 have significant structural and functional similarities. The DNA-binding domain of p73 shares 62% amino acid identity with p53 (Melino et al., 2003) . This translates into similar functional properties; p73 and p53 transactivate an overlapping set of target genes, induce apoptosis, cell cycle arrest and cellular senescence. However, there are also significant differences. In contrast to p53, which is mutated in human tumors, p73 is frequently overexpressed without mutations. We, along with others, have hypothesized that this occurs because the p73 gene (TP73) can produce additional isoforms with oncogenic properties (Cam et al., 2006; Zaika and El-Rifai, 2006; Buhlmann and Putzer, 2008) . p73 isoforms can be divided into two groups, termed TA and DN (or DTA). TAp73 isoforms contain the N-terminal transactivation domain, are induced by DNA damage and potentially have tumor suppressor properties (Lin et al., 2004; Tomasini et al., 2008) . In contrast, DN isoforms partially or completely lack the transactivation domain and are potent dominant-negative inhibitors of p53 and TAp73. An extensive body of data show that they may behave as oncogenes. We found that DNp73 immortalizes murine cells and cooperates with other oncogenes in cellular transformation of primary mouse embryonic fibroblasts (Petrenko et al., 2003) . Subcutaneous injection of these transformed cells into immunocompromised mice produces tumors. DNp73 also inhibits differentiation and promotes malignant transformation of myobasts (Cam et al., 2006) . Transgenic expression of DNp73 leads to tumor formation in mice (Tannapfel et al., 2008) . It has also been reported that DNp73 is overexpressed in a number of human tumors (Casciano et al., 2002; Vilgelm et al., 2008b) .
Regulation of DNp73 expression remains largely unknown. The TP73 gene has two promoters, P1 and P2. The P1 promoter mediates expression of TA isoforms, whereas the intragenic P2 promoter is responsible for DNp73 transcription (Vilgelm et al., 2008a) . In addition, aberrant splicing of TAp73 transcripts may lead to DNp73 increase (Stiewe et al., 2004) . Currently, p53
and TAp73 are the only well characterized transcription factors that are known to regulate the P2 promoter. The studies found that induction of DNp73 leads to p53 and TAp73 inhibition and creates a feedback mechanism that negatively controls their transcription activities. (Grob et al., 2001; Kartasheva et al., 2002; Nakagawa et al., 2002) . However, because of the frequent tumor-specific inactivation of p53, it is unlikely that p53 is a major regulator of DNp73 transcription in tumor tissues.
HIC1 (hypermethylated in cancer) is a sequence-specific transcriptional repressor that has a tumor suppressor role. Ectopic expression of HIC1 suppresses growth and survival of tumor cells (Wales et al., 1995) . Germline disruption of one allele of the HIC1 gene predisposes mice to spontaneous tumors in which the wild-type allele is inactivated. HIC1 is also frequently inactivated by epigenetic mechanisms in gastric and other human tumors (summarized in Chen and Baylin, 2005) .
In this study, we investigated the regulation of DNp73 expression in human upper gastrointestinal tumors and found that HIC1 is involved in transcriptional repression of the DNp73 promoter in gastric and esophageal epithelial cells.
Results and discussion

Expression of DNp73 in gastric tumors
The clinicopathological role of DNp73 has not been previously assessed in gastric and esophageal tumors. Therefore, we first analyzed the expression of DNp73 protein using immunohistochemistry with DNp73-specific antibody. Three tissue microarray blocks composed of the clinical material from 185 patients with gastric, gastroesophageal junction and esophageal cancers, who had surgical resection at Vanderbilt University Medical Center, United States and the University of Barcelona, Spain were analyzed by a pathologist in a blind manner. We found that expression of the DNp73 protein is significantly increased in the nuclei and cytoplasms of tumor epithelial cells compared with the normal mucosa ( Figure 1a ). The nuclear and cytoplasmic expressions of DNp73 were further analyzed for association with clinicopathological variables. We found a significant difference in survival between gastric cancer patients with high levels of nuclear DNp73 and those with a negative/weak expression (P ¼ 0.005, log-rank test). The median survival time for patients with an increased nuclear DNp73 was 20 months, whereas that of patients with a negative/weak expression was 47 months (Figure 1b, upper panel) . Similarly, elevated levels of cytoplasmic DNp73 were significantly correlated with a poor survival rate of gastric cancer patients (P ¼ 0.009, log-rank test; Figure 1b , lower panel). Cytoplasmic (but not nuclear) expression of DNp73 was also marginally associated (P ¼ 0.05) with the survival of esophageal and gastroesophageal junction cancer patients (Supplementary Table 1 ). There were no statistically significant associations between DNp73 expression and other clinicopathological parameters except between cytoplasmic DNp73 and lymph node metastases and pT classification (Supplementary Table 2 and 3). In multivariate analysis using Cox proportional hazards model, DNp73 was not an independent prognostic factor (
To analyze mechanisms of DNp73 regulation, we next examined the expression of DNp73 mRNA in 31 gastric and 7 esophageal tumors. We used real-time PCR with primers, which specifically amplify DNp73 transcripts derived from the P2 promoter. Our analysis of the DNp73 mRNA expression found a frequent overexpression of this transcript in 29% (9/31) gastric tumors ( Figure 1c , left panel) and in 57% (4/7) esophageal tumors ( Figure 1c , right panel). The overexpression was defined as an arbitrary cut-off, delineating tumors with five fold or higher mRNA upregulation compared with the average normal level in 16 normal gastric and 4 normal esophageal mucosal biopsies (shown as a dashed line in Figure 1c ).
The tumor-specific overexpression of DNp73 is consistent with the oncogenic function of DNp73. To further confirm this, non-neoplastic immortalized murine gastric epithelial cells, which harbor a temperaturesensitive mutation of the SV40 large T antigen (ts-TAg), were transfected with DNp73a and then cultured in softagar until visible colonies were formed. Control vectortransfected cells failed to efficiently grow forming a few small size colonies in soft agar. In contrast, DNp73a facilitated the anchorage-independent growth DNp73-specific antibody (Imgenex, San Diego, CA, USA; 1:200 dilution) was used in this analysis. The immunoreactivity was interpreted as positive when more than 10% of tumor cells showed positivity for nuclear DNp73. Staining specificity was verified by omitting a primary antibody step in the protocol. The detailed immunohistochemistry protocol was described previously (Vilgelm et al., 2008b) . The analyzed tissue samples were obtained after approval by the Institutional Review Boards. (b) Kaplan-Meier survival curve for gastric cancer patients stratified according to nuclear and cytoplasmic DNp73 expression. Statistical significance was assessed by the log-rank test. and produced multiple large size colonies suggesting that DNp73a has an oncogenic role in gastric epithelial cells (Figure 1d ).
Regulation of DNp73
As shown above, DNp73 transcription is significantly increased in analyzed tumors. Currently, little is known about the regulation of the alternative P2 promoter that mediates the transcription of DNp73. To investigate this promoter, we initially carried out its analysis in silico. Using comparative sequencing analysis with the rVista (v. 2.0) computational tool (Loots and Ovcharenko, 2004) , DNp73 promoter was investigated for potential cis-regulatory elements. On the basis of comparison of homologous sequences from different species, we identified a small region (B250 bp) in the DNp73 promoter that is highly conservative in human, mouse, rat, chicken, and frog (Figure 2a ). Further analysis of this region found three potential binding sites for zincfinger transcriptional repressor, HIC1. The highest similarity to the HIC1 consensus-binding site was found for the site located at position À80/À69 (Figure 2a) . The presence of the HIC1-binding site was also confirmed by the Genomatix MatInspector software (Figure 2b) .
To further investigate the regulation of DNp73, gastric epithelial cell lines, SNU1 and AGS were cotransfected with HIC1 and luciferase reporter, which expresses luciferase under the control of 2.2 kb DNp73 promoter. As is shown in Figure 3a , transfection of HIC1 significantly decreased the luciferase activity suggesting that HIC1 is a negative regulator of DNp73 promoter. Consistent with this analysis, we found that ectopic HIC1 also suppressed the expression of both endogenous DNp73 mRNA (Figure 3b ) and protein ( Figure 3d, upper panel, compare lanes 5 and 6) . To analyze the effect of endogenous HIC1, SNU1, HET-1A, and AGS cells were transfected with small interfering RNA against HIC1. HET-1A esophageal cells were selected as a prototypical non-neoplastic cell line as it is derived from normal epithelial cells. Inhibition of endogenous HIC1 in SNU1 and HET-1A cell lines not only significantly increased levels of DNp73 mRNA (Figure 3c ) but also DNp73 protein confirming that HIC1 negatively regulates DNp73 (Figure 3d , bottom panel, compare lanes 3 and 4). Interestingly, the effect of HIC1 small interfering RNA was significantly diminished in AGS cells that express low levels of the endogenous HIC1 mRNA and protein (Figure 3c , bottom panel and data not shown).
Next, we asked whether this effect is mediated by direct binding of HIC1 to the DNp73 promoter. SNU1 cells were transfected with Flag-tagged HIC1 expression vector and analyzed for HIC1 binding to DNp73 promoter using chromatin immunoprecipitation (ChIP). p53, which is known to be bound to this promoter, was used as an additional positive control. Unspecific IgG and amplification with distal unspecific primers were used as negative controls. Positions of all primers are shown in Figure 4b (bottom panel). The ChIP analysis with Flag antibody found strong binding of HIC1 to the DNp73 promoter (Figure 4a ). To confirm binding of the endogenous HIC1, we also carried out ChIP analysis using HIC1 antibody. As shown in Figure 4b , similar to the ectopic protein, the endogenous HIC1 binds to the DNp73 promoter.
However, the ChIP analysis does not provide sufficient resolution to precisely characterize the HIC1-binding site. As so, we conducted deletion analysis and sitedirected mutagenesis of the DNp73 promoter. We found that a small deletion of 20 bp that encompasses a significant part of the HIC1-binding site led to a complete loss of response to HIC1 suppression in MKN75 cells (Figure 4c) . A similar effect was also seen in other cells, AGS and SNU1 (data not shown), suggesting that HIC1 binds to this site. To further confirm that this binding site is responsible for the effect of HIC1 and minimize effects of other transcription Figure 3 HIC1 inhibits DNp73 expression. (a) HIC1 inhibits activity of DNp73 luciferase reporter in SNU1 and AGS gastric epithelial cells. Cells were transfected with luciferase reporter containing a 2.2 kb fragment of the DNp73 promoter together with HIC1 expression plasmid or control empty vector. DNp73 promoter activity was measured 24 h after transfection using Dual-Luciferase Reporter Assay kit (Promega, Madison, WI, USA) as described previously (Vilgelm et al., 2008b) . SNU1 and AGS cells (American Type Culture Collection, Manassas, VA, USA) were maintained in Ham's F-12 media (Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum. Transfections were carried out with FuGENE 6 reagent (Roche, Indianapolis, IN, USA) using the manufacturer's protocol. DNp73 luciferase reporter was kindly provided by Dr Melino (University of Rome, Italy). Human HIC1 expression plasmid was a generous gift of Dr Leprince (Institut de Biologie de Lille, France). (b) Downregulation of endogenous DNp73 mRNA after HIC1 transfection into SNU1 and AGS cells. Cells were transfected with Lipofectamine 2000 (Invitrogen) using the manufacturer's protocol. mRNA levels were measured by quantitative PCR 48 h after transfection as described previously (Vilgelm et al., 2008b) . Primers used for quantitative PCR are shown in Supplementary Table 4 Supplementary Table 4 . (c) Deletion or mutation of the HIC1-binding site attenuates the inhibitory function of HIC1 at the DNp73 promoter. MKN75 gastric cancer cells were transfected with the indicated luciferase reporters and HIC1 activity was then analyzed using reporter assay. Bottom panel shows sequences of DNp73 luciferase reporters. Mutated DNp73 reporter was generated by site-directed mutagenesis using the site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA). MKN75 were maintained in RPMI media (Invitrogen) supplemented with 10% fetal bovine serum. DNp73 luciferase reporter was kindly provided by Dr Melino. (d) HIC1 inhibits expression of DNp73 mRNA induced by p53 and TAp73. MKN28 gastric epithelial cells were maintained in RPMI medium supplemented with 10% fetal bovine serum. Cells were transfected with the indicated plasmids and expression of DNp73 mRNA was analyzed using quantitative PCR as described previously (Vilgelm et al., 2008b) . factors, we introduced four point mutations into the HIC1-binding site and tested the mutated promoter using reporter analysis (Figure 4c ). These specific mutations completely suppressed the inhibitory effect of HIC1 on the DNp73 promoter further supporting our data. Notably, these mutations did not inhibit activation of the promoter by p53 even though p53 and HIC1-binding sites are located in close proximity (Figure 4c , left panel). In fact, p53 activation of the mutant DNp73 promoter was approximately 1.5-fold higher than that of the wild-type promoter. This suggests that endogenous HIC1 may interfere with the regulation of the DNp73 reporter by p53. To further investigate functional interaction between HIC1 and p53 at the DNp73 promoter we transfected MKN28 cells with either the p53 plasmid alone or in combination with HIC1. We found that HIC1 inhibited activation of DNp73 expression by p53 (Figure 4d) . Notably, it also inhibited activity of TAp73, which has also been shown to regulate the DNp73 expression through the same p53-binding site (Nakagawa et al., 2002) (Figure 4d ). Similar results were obtained in other cell lines including AGS, SNU1 and HET-1A (data not shown).
To confirm our findings, we analyzed the correlation between HIC1 and DNp73 mRNA in human primary gastric and esophageal tumors. Only a trend of inverse correlation between HIC1 and DNp73 (r ¼ À0.22, P ¼ 0.2; Spearman rank correlation) was found in the combined set of 26 gastric and esophageal specimens (Supplementary Figure 1B) . However, in the subset of esophageal tissues (n ¼ 11) significant inverse correlation (r ¼ À0.68, P ¼ 0.03) was found (Supplementary Figure  1C) . Thus, HIC1 may contribute to the DNp73 regulation in vivo. In addition, we evaluated p53 and TAp73 as potential regulators of the DNp73 transcription. The DNp73 mRNA expression was not significantly associated with the mutational status of p53 (P ¼ 0.11, Wilcoxon rank sum test) suggesting that p53 is not a main regulator of DNp73 in these tumors. In contrast, we found that the expression of DNp73 mRNA positively correlates with TAp73 (r ¼ 0.72, Po0.001) in gastric and esophageal tumors (Supplementary Figures  1A, 1D ). This is consistent with the important role of TAp73 in the regulation of DNp73 expression (Nakagawa et al., 2002) .
Taken together, our analyses show, for the first time, that DNp73 has important role in gastric tumorigenesis and its increased expression is associated with poor survival of patients with gastric tumors. We found that HIC1 tumor suppressor binds to the DNp73 promoter and inhibits its activity as well. Our data suggest that loss of HIC1, which frequently occurred in human gastric tumors (Kanai et al., 1998) , may lead to the upregulation of DNp73. As a result, DNp73 inhibits p53 and TAp73 activities and promotes gastric tumorigenesis.
